Trevi Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell TRVI and other ETFs, options, and stocks.

About TRVI

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. 

CEO
Jennifer L. Good
CEOJennifer L. Good
Employees
26
Employees26
Headquarters
New Haven, Connecticut
HeadquartersNew Haven, Connecticut
Founded
2011
Founded2011
Employees
26
Employees26

TRVI Key Statistics

Market cap
1.36B
Market cap1.36B
Price-Earnings ratio
-28.79
Price-Earnings ratio-28.79
Dividend yield
Dividend yield
Average volume
1.58M
Average volume1.58M
High today
$10.84
High today$10.84
Low today
$10.25
Low today$10.25
Open price
$10.62
Open price$10.62
Volume
413.38K
Volume413.38K
52 Week high
$14.39
52 Week high$14.39
52 Week low
$3.77
52 Week low$3.77

Stock Snapshot

The current Trevi Therapeutics(TRVI) stock price is $10.59, with a market capitalization of 1.36B. The stock trades at a price-to-earnings (P/E) ratio of -28.79.

On 2026-01-30, Trevi Therapeutics(TRVI) stock traded between a low of $10.25 and a high of $10.84. Shares are currently priced at $10.59, which is +3.3% above the low and -2.3% below the high.

Trevi Therapeutics(TRVI) shares are trading with a volume of 413.38K, against a daily average of 1.58M.

In the last year, Trevi Therapeutics(TRVI) shares hit a 52-week high of $14.39 and a 52-week low of $3.77.

In the last year, Trevi Therapeutics(TRVI) shares hit a 52-week high of $14.39 and a 52-week low of $3.77.

TRVI News

Simply Wall St 3d
A Look At Trevi Therapeutics Valuation After Positive Phase 2b CORAL Trial Publication

Trevi Therapeutics (TRVI) recently reported that primary results from its Phase 2b CORAL trial of oral nalbuphine ER in idiopathic pulmonary fibrosis chronic co...

A Look At Trevi Therapeutics Valuation After Positive Phase 2b CORAL Trial Publication

Analyst ratings

100%

of 12 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own TRVI. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.